The HDAC8 Knockout AGS Polyclonal Cells product comprises a heterogeneous population of AGS gastric adenocarcinoma cells in which the HDAC8 gene has been disrupted using CRISPR/Cas9 technology. This polyclonal knockout pool provides a physiologically relevant loss-of-function model for investigating HDAC8-dependent processes without the clonal selection artifacts associated with monoclonal lines. By targeting the endogenous HDAC8 locus, the cell population enables robust and reproducible ablation of HDAC8 expression, serving as a versatile tool for functional genomics and drug discovery studies.
AGS is an adherent, epithelial-like cell line originally derived from a human gastric adenocarcinoma. It exhibits a hypertriploid karyotype, lacks functional p53, and expresses cytokeratins characteristic of its epithelial origin. Widely adopted as a model for gastric cancer, AGS cells are instrumental in dissecting signaling pathways, evaluating chemotherapeutic agents, and investigating mechanisms of tumorigenesis and metastasis. Their well-characterized genomic landscape and reliable growth characteristics make them a suitable platform for generating knockout derivatives.
HDAC8 encodes a class I histone deacetylase that catalyzes the removal of acetyl groups from lysine residues on histone tails, particularly H3 and H4, as well as on non-histone substrates including p53, SMC3, ER??, and cortactin. This deacetylation promotes chromatin compaction and transcriptional repression. HDAC8 activity is regulated by upstream factors such as MYC, HIF1A, E2F1, STAT3, and p53. It deacetylates p53 at key lysine residues, attenuating p53 transcriptional activity and pro-apoptotic functions, and modulates cohesin complex dynamics through deacetylation of SMC3 and RAD21. Interactions with HSP90 and MTA1 further integrate HDAC8 into chromatin remodeling and nuclear receptor signaling networks, positioning it as a critical node linking epigenetic regulation with cell cycle progression, apoptosis, and epithelial-mesenchymal transition.
In the AGS gastric cancer context, HDAC8 knockout eliminates a key enzymatic activity that supports oncogenic phenotypes. Given the p53-deficient background of AGS cells, disruption of HDAC8 may partially restore p53-like responses or isolate the contributions of other HDAC isoforms. This model enables dissection of HDAC8-specific roles in gastric cancer cell proliferation, survival, and chemoresistance. It is particularly suited for investigating how HDAC8-mediated deacetylation of substrates influences downstream signaling and for evaluating isoform-selective HDAC inhibitors as potential therapeutics.
Researchers can employ this polyclonal HDAC8 knockout cell population for a wide range of functional assays, including Western blot analysis of histone acetylation marks such as H3K9ac and H4K16ac, RT-qPCR profiling of HDAC8-regulated genes, and cell cycle or apoptosis analyses via flow cytometry. The model facilitates drug target validation with HDAC8-specific inhibitors, co-immunoprecipitation experiments to map HDAC8 interactomes, and ChIP-qPCR studies of histone modification changes at gene promoters. It also serves as a robust platform for investigations into chemotherapy resistance and epigenetic therapy. For further information, please contact Ascent Research.
